SeraCare refocuses energies on in vitro Dx work

SeraCare Life Sciences has sold off some of its business lines in order to refocus its energies on the in vitro diagnostics market. Mass High Tech reports that the Milford, MA, company sold its biorepository, biobanking and laboratory services business to Maryland's Precision Health Holdings, though neither side is discussing financial terms. The remaining company has 150 employees focused on in vitro diagnostics research and processing, and clinical laboratory services. SeraCare also appointed a number of new executives. The changes follow Linden Capital Partners' purchase of SeraCare last year. Story

Suggested Articles

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.